Telisotuzumab vedotin shows promising results in asian patients with c-Met overexpressing NSCLC

The c-Met-directed antibody-drug conjugate telisotuzumab vedotin demonstrated durable responses and an acceptable safety profile in patients of Asian race with c-Met protein-overexpressing, epidermal growth factor receptor (EGFR) wildtype (WT), locally advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC), according to research presented today at the International Association for the Study of Lung Cancer’s 2024 World Conference on Lung Cancer.

Redefining global health regulation: Key steps for equitable access during emergencies

Three high-impact steps could be taken by global health leaders to reshape the global regulatory framework and help address the pressing need for equitable access

August 4, 2024

PharmAla Completes Historic First Shipment of MDMA and Psilocybin to Cortexa | Psychedelic Invest

PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class

November 7, 2023

‘Until it is fixed’: Congress ramps up action on Social Security clawbacks

The Senate Finance Committee is ramping up oversight of Social Security’s overpayment problem and plans to meet with the agency every month “until it is

December 15, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.